

# Medtronic to present new data that adds to the proven success of MiniMed™ 780G system at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting

The company will initiate a phased launch of its disposable Simplera™ CGM at the meeting, its smallest and most comfortable CGM to-date that's integrated with the InPen™ smart insulin pen

DUBLIN - September 25, 2023 - [Medtronic plc](#) (NYSE:MDT), a global leader in healthcare technology, today announced its participation in the upcoming European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany on Oct. 2-6, 2023. During the conference, Medtronic will present new data across its holistic portfolio of solutions and will begin a phased launch of its recently CE Mark approved Simplera™ CGM. Medtronic's newest and smallest CGM to-date is integrated with the InPen™ smart insulin pen, which together offers a Smart MDI system that provides personalized dosing guidance to help simplify diabetes management for MDI users. Data will include evidence on the highly adaptive algorithm in the MiniMed™ 780G system across different continents and in changing physical and cultural environments, demonstrating its ability to serve anyone who desires better outcomes. Data will also highlight the ability of the system to more tightly manage Time in Range compared to previous systems. Additionally, real-world data from its InPen smart insulin pen will be shared to display the benefits of actionable dosing information on outcomes.

## Scientific Presentations

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.

### MiniMed™ 780G System Data Presentations

- "Consistent performance of the MiniMed 780G system across continents: a world-wide real-world analysis" - short oral discussion (830) by Tim van den Heuvel, Ph.D., Principal Medical Affairs Specialist, Medtronic Diabetes on Tuesday, October 3 at 1:45 p.m. CEST (Venue: Short Oral Platform B)
- "The use of optimal system settings in real-world MiniMed 780G system users has a large impact on increasing the time in tight glucose range" - oral presentation (223) by Javier Castañeda, Senior Statistics Manager, Medtronic Diabetes on Thursday October 5 at 3:30 p.m. CEST (Venue: Paris Hall)
- "Real-world evidence from MiniMed 780G system users in Europe, Middle East, and Africa: results from 61481 users across 31 countries" - oral presentation (224) by Arcelia Arrieta, M.Sc., Principal Clinical IT Developer, Medtronic Diabetes on Thursday October 5 at 3:45 p.m. CEST (Venue: Paris Hall)
- "The MiniMed 780G system adapts to substantial changes in daily routine: lessons from real-world users during Ramadan" - short oral discussion by Mohammed Al-Sofiani, Ph.D, M.D., Assistant Professor of Endocrinology, Diabetes & Metabolism, on behalf of Medtronic Diabetes, on Thursday, October 5 at 2:00 p.m. CEST (Venue: Short Oral Platform F)

### InPen™ Presentations

- InPen™ smart insulin pen plus continuous glucose monitoring (CGM) identifies missed correction opportunities: Impact on glycemia - short oral discussion (768) by Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences on Tuesday, October 3 at 12:30 p.m. CEST (Venue: Short Oral Platform A)
- Why CGM alone is not enough: Low actionability of CGM alerts without considering impact of active insulin - short oral discussion (758) by Madison Smith, Ph.D., R.N., CDCES, R&D Senior Clinical Product Manager, Medtronic Diabetes on Thursday, October 5 at 12:45 p.m. CEST (Venue: Short Oral Platform E)

### Medtronic Sponsored Events

In addition, the following symposia will feature discussions with Medtronic and independent speakers. Details are as follows:

- **Symposium:** "Establishing the role of the MiniMed™ 780G system in the treatment of type 1 diabetes: world-wide experience" on Tuesday, October 3 at 7:45 a.m. CEST. The event will feature:

Expert	Topic
Prof. Olga Kordonouri (Germany)	Moving towards new glycemic treatment goals (Time in Tight range) for young people with type 1 diabetes: insights from the SWEET registry
Prof. Ohad Cohen (Israel)	Insights from real-world evidence in glycemic metrics: something new, something old
Prof. Partha Kar (United Kingdom)	Expanding the access to the MiniMed™ 780G system on a national level: the UK experience
Consistent real-world experience with MiniMed™ 780G system around the world	
Prof. Mohammed Al-Sofiani (Kingdom of Saudi Arabia)	What happens during the Ramadan?
Dr. V. Mohan (India)	Results in India
Prof. Bruno Grassi (Chile)	Results in Latin America

- **Exhibit Booth** featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for healthcare professionals and patients. **In-Booth Presentations** will include:

- “New generation of Smart MDI therapy,” on Tuesday, October 3 at 10:30 a.m. CEST and Wednesday, October 4 at 10:30 a.m. CEST by Madison Smith, Ph.D., R.N., CDCES, R&D Senior Clinical Product Manager, Medtronic Diabetes

- **Hot Topics:**

- “The adaptation of the MiniMed™ 780G algorithm in changing environments” on Thursday, October 5 at 12:15 p.m. CEST, with presentations from Prof. Goran Petrovksi, Dr. Nancy Elbarbary and Dr. Klemen Dovč
- “The first experience with the Medtronic Smart MDI system: Transforming MDI therapy for type 1 diabetes” on Friday, October 6 at 11:30 a.m. CEST by Prof. Peter Adolfsson (Sweden) and Madison Smith, Ph.D., R.N., CDCES, R&D Senior Clinical Product Manager, Medtronic Diabetes

#### **About the Diabetes Business at Medtronic**([www.medtronicdiabetes.com](http://www.medtronicdiabetes.com))

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

#### **About Medtronic**

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit [www.Medtronic.com](http://www.Medtronic.com) and follow [@Medtronic](https://twitter.com/Medtronic) on Twitter and [LinkedIn](https://www.linkedin.com/company/medtronic).

**Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.**

[https://stage.mediaroom.com/minimed\\_mr/2023-09-25-Medtronic-to-present-new-data-that-adds-to-the-proven-success-of-MiniMedTM-780G-system-at-the-European-Association-for-the-Study-of-Diabetes-EASD-59th-Annual-Meeting](https://stage.mediaroom.com/minimed_mr/2023-09-25-Medtronic-to-present-new-data-that-adds-to-the-proven-success-of-MiniMedTM-780G-system-at-the-European-Association-for-the-Study-of-Diabetes-EASD-59th-Annual-Meeting)